ArticleCancer causes & control : CCC2025
Differences in prostate cancer treatment receipt and timeliness of treatment between African American/Black and White Iowans.
Article in Cancer causes & control : CCC, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Racial and ethnic disparities in esophageal cancer survival are greatest at curable stages: a population-based study.Cancer causes & control : CCC · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-Hispanic Black (NHB) men face higher prostate cancer (PCa) mortality rates compared to other racial/ethnic groups. Factors contributing to these disparities, particularly concerning healthcare system factors, remain uncertain. We investigate differences in treatment receipt and timeliness between NHB, non-Hispanic White (NHW) and Hispanic Iowans, examining variations across treatment facilities.
methodsDemographic, tumor, treatment, and hospital characteristics of PCa patients 40-99 years were obtained from the Iowa Cancer Registry (2010-2020). We used logistic regression to estimate the odds of receiving definitive treatment, time to treatment, and the type of treatment received.
resultsAmong 18,747 PCa patients, 18,197 (97.1%) were NHW, 550 (2.9%) NHB, and 155 Hispanic (0.83%). NHB men were younger. The odds of receiving definitive treatment among advanced stage patients were significantly lower for NHBs compared to NHWs (adjusted odds ratio-AOR- 0.39; 95% CI 0.26-0.59). More NHBs underwent PCa treatment at either NCI-designated or CoC-accredited facilities. NHBs receiving care at an NCI-designated center or at a non-accredited center were less likely to receive definitive treatment compared to NHWs. Furthermore, NHBs with advanced PCa had diminished odds of receiving definitive treatment regardless of the status of the treatment facility (NCI: AOR = 0.34; 95% CI 0.13 - 0.93; CoC only: AOR = 0.47; 95% CI 0.29 - 0.76; Neither: AOR 0.24; 95% CI 0.10-0.60).
conclusionNHB men with an advanced staging had lower odds of receiving definitive treatment across treatment settings. Further research and intervention are needed to reduce these disparities and improve PCa outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.